CRISPR THERAPTC (NASDAQ:CRSP) Director Kurt Von Emster sold 41,312 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $17.63, for a total transaction of $728,330.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Kurt Von Emster also recently made the following trade(s):
- On Thursday, August 17th, Kurt Von Emster sold 34,141 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $19.06, for a total transaction of $650,727.46.
- On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $19.59, for a total transaction of $1,088,596.71.
- On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $18.63, for a total transaction of $660,861.99.
- On Friday, August 4th, Kurt Von Emster sold 50,477 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.81, for a total transaction of $898,995.37.
- On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.51, for a total transaction of $96,515.12.
- On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.60, for a total transaction of $579,568.00.
- On Friday, July 14th, Kurt Von Emster sold 69,859 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.84, for a total transaction of $1,176,425.56.
- On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.56, for a total transaction of $529,787.52.
- On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.26, for a total transaction of $69,170.04.
- On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.90, for a total transaction of $730,113.80.
Shares of CRISPR THERAPTC (NASDAQ:CRSP) opened at 18.34 on Friday. CRISPR THERAPTC has a 12-month low of $11.63 and a 12-month high of $25.00. The firm’s 50-day moving average is $17.38 and its 200-day moving average is $17.51. The company’s market capitalization is $744.44 million.
CRISPR THERAPTC (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.06. CRISPR THERAPTC had a negative net margin of 406.61% and a negative return on equity of 47.46%. The business had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. The business’s revenue for the quarter was up 350.0% on a year-over-year basis. On average, equities research analysts anticipate that CRISPR THERAPTC will post ($2.43) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/19/insider-selling-crispr-theraptc-nasdaqcrsp-director-sells-41312-shares-of-stock-updated-updated.html.
A number of equities research analysts have issued reports on the stock. Cann assumed coverage on shares of CRISPR THERAPTC in a report on Monday, July 17th. They set a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a report on Tuesday, July 18th. SunTrust Banks, Inc. assumed coverage on shares of CRISPR THERAPTC in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target for the company. Finally, Chardan Capital restated a “buy” rating on shares of CRISPR THERAPTC in a report on Monday, August 14th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. CRISPR THERAPTC presently has an average rating of “Buy” and a consensus target price of $21.92.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its position in shares of CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the period. Monashee Investment Management LLC increased its stake in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares in the last quarter. Paulson & CO. Inc. acquired a new stake in CRISPR THERAPTC during the first quarter worth about $1,099,000. Credit Suisse AG acquired a new stake in CRISPR THERAPTC during the first quarter worth about $1,742,000. Finally, IHT Wealth Management LLC acquired a new stake in CRISPR THERAPTC during the first quarter worth about $110,000. Institutional investors and hedge funds own 24.08% of the company’s stock.
About CRISPR THERAPTC
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.
